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Exploring the factors 
that trigger vasospasm 
in the coronary arteries 
The elusive issue of the causes and character 
of coronary-artery vasospasm is the principal 
research interest of Richard A . Cohen, M . D . , 
and his associates. 
Vasospasm plays an important role i n the 
funct ioning of blood vessels throughout the 
body, says Dr. Cohen. I t has been identif ied 
as a cause of angina pectoris, migraine head-
aches and Raynaud's phenomenon, among 
other conditions. 
A key feature of the coronary arteries, 
notes the investigator, a member of the Pe-
ripheral Vascular Section, is that they react 
i n the opposite way f r o m other arteries to 
s t i m u l a t i o n through the sympathetic nervous 
system's adrenergic pathways. When norepi-
nephrine is released by the nerves i n coro-
nary-artery walls , the result is vasodilation, 
not vasoconstriction. 
The apparent reason is that the neuro-
transmitter is acting p r i m a r i l y on the vaso-
dilatory beta adrenergic receptors i n the 
smooth muscle, not the vasoconstricting al-
pha receptors. "That 's w h y propanalol, 
w h i c h blocks the beta adrenergic receptors, 
can cause problems i n some patients w i t h 
angina," says Dr. Cohen, w h o is also an as-
sistant professor of medicine at BUSM. 
A complex phenomenon 
Though there's obviously m u c h to be 
gained f r o m shedding l i ght on the mecha-
nisms under ly ing vasospasm, they do not 
y ie ld readily to efforts at unraveling 
them. For one th ing , a range of factors are 
involved i n producing constr ict ion i n the 
coronary arteries. Cholesterol, for example, 
can magnify the effects of important vaso-
constrictive s t i m u l i . For another, platelets, 
key players i n arterial regulation, are subject 
to an elaborate feedback system. "Platelets 
release several mediators involved i n vaso-
spasm," explains Dr. Cohen, "and many of 
the released substances i n t u r n accelerate the 
act ivation of the platelets." 
Yet w h i l e the regulatory machinery of 
vasospasm is complex, that doesn't mean 
c l in ica l ly useful findings l ie decades off. O n 
Dr. Cohen (left) and technician Kevin Zitnay ex-
amine charts showing contraction responses of 
canine arteries to varied stimuli. Arteries are 
mounted on tiny wire stirrups, permitting strength 
of contractions to be measured. 
the contrary. Dr. Cohen suggests that i f the 
key influences on vasospasm are identif ied, 
c l inical applications may soon fo l low. 
One starting point for any exploration of 
vasospasm is the arterial endothel ium, re-
cently identi f ied as a major regulator of vaso-
constrict ion. Studies of the endothel ium, 
says Dr. Cohen, demonstrate that i t harbors 
a diverse range of regulatory tools: hormone 
receptors, ion-exchange pumps, and both 
synthesizing and degrading enzymes. 
One of the endothelium's abilities is that, 
i n response to certain s t i m u l i , i t can trigger a 
relaxation of the blood vessel. " T h i s effect 
was first discovered w i t h acetylcholine," 
says Dr. Cohen. " W h e n it 's released and 
comes i n contact w i t h the endothel ium in 
vitro, the result is a strong relaxation effect. 
It 's clear that the endothel ium is releasing 
some sort of mediator ." 
Continued on page 2 
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Studying the impact of platelets 
Dr. Cohen's group is part icularly interested 
i n the interactions between the endothel ium 
and platelets, and i n the impact of platelet-
generated mediators on other parts of the 
vessel. They have done extensive in vitro 
studies i n w h i c h rings of animal arteries i n 
various states are exposed to platelets or i n -
dividual mediators. 
" W h e n we cause platelets to aggregate i n 
one of these rings, we see t w o contradictory 
types of responses," explains Dr. Cohen. 
"The response mediated by the endothel ium 
is a relaxation, w h i l e the vessel's direct re-
sponse to the platelets is a contract ion." 
The contraction effect is present even 
w h e n the endothel ium is intact , and studies 
by Dr. Cohen's group have helped to show 
why. The group has found that platelet prod-
ucts—among t h e m thromboxane and sero-
tonin—can penetrate the endothel ium, and 
can thereby influence the vessel's funct ion-
ing i n various ways. 
Serotonin, for example, can l i n k up d i -
rectly w i t h receptors on the smooth muscle. 
I t also can act on receptors near the endings 
of the adrenergic nerves that control the ar-
terial blood f low. I n both instances, he adds, 
the mediator promotes constrict ion. 
"We don't k n o w exactly what serotonin 
does w h e n i t acts on the nerve endings," 
says Dr. Cohen. "However, we do k n o w that 
i t inhib i t s the release of norepinephrine, and 
that leads to a greater contraction of the ves-
sel." 
When constriction predominates 
The abi l i ty of platelet-generated mediators 
to produce such effects probably has l i t t l e 
relevance to the funct ioning of normal ves-
sels. Platelets don't generally collect on nor-
mal tissue. Even w h e n they do—as, for ex-
ample, w h e n there's endothelial damage 
upstream—their net impact is strongly 
weighted toward relaxation because of their 
s t imula t ing effect on the endothel ium. 
If the endothel ium is damaged, however, 
i t 's another matter. "We f i n d that w h e n we 
remove the endothel ium f r o m an artery, and 
expose i t to platelets, the result is a strong 
contract ion," says Dr. Cohen. He says the 
f inding is convincing evidence that the direct 
effects of the platelet mediators on the 
smooth muscle and the nerves are dominat-
ing the vessel's response to the mediators. 
Other experimental evidence suggests that 
i t 's not necessary for the endothel ium to be 
el iminated altogether to produce vasospasm. 
Endothelial damage l ike that done by athero-
sclerosis appears to be enough to t ip the bal-
ance strongly toward contraction. 
Besides looking at the impact of platelets 
on coronary arteries, D r Cohen's group has 
also explored w h i c h platelet products are 
most i n f l u e n t i a l i n vasospasm. 
Serotonin's central role 
" I n studies I began w h e n I was at the 
Mayo Cl in ic , I found that serotonin was 
clearly responsible for the most direct ef-
fects," says Dr. Cohen. " T h a t surprised some 
people, because thromboxane has been con-
sidered the most potent vasoconstrictor i n 
platelets." 
The group also has discovered that sero-
t o n i n probably has chronic effects on blood 
vessels as w e l l as acute ones. 
" W h e n we put a balloon catheter in to an 
animal's artery and remove the endothel ium, 
we get platelets aggregating i n there," ex-
plains Dr. Cohen. " W h e n we go back 24 
hours later and measure the serotonin i n the 
sympathetic nerves innervat ing those ves-
sels, we f i n d very h igh levels. This adversely 
affects the funct ioning of those nerves." 
This f inding points to long-term buildups 
of serotonin i n the nerves as major contrib-
utors to vasospasm. Dr. Cohen believes 
there's solid indirect evidence for such an ef-
fect. 
" I f there's chronic platelet aggregation," he 
explains, "and the serotonin becomes incor-
porated i n t o the nerve ending, i t 's l i k e l y to 
remain there for a long t ime , because once 
it 's i n there i t ' s protected f r o m metabolic 
degradation." 
Implications for treatment 
What is the potent ial significance of such 
findings for patients w i t h cardiovascular dis-
ease? " I f you establish that serotonin plays 
a major role i n vasospasm, that probably 
isn't going to mean m u c h for the angina pa-
t ient at the t i m e he's experiencing symp-
toms , " says Dr. Cohen. "There are an a w f u l 
lo t of medications, l ike the calc ium channel 
blockers and nitroglycerin, that can reduce 
arterial constr ic t ion . " 
O n the other hand, he says, the findings 
could speed the search for preventive thera-
pies. If important mediators of vasospasm are 
collecting i n the nerves, for example, i t 
m i g h t be possible to reverse the accumula-
t ion , or at least to moderate the mediators' 
effects. 
I n fact, he notes. Jay D . Coffman, M . D . , 
chief of the Peripheral Vascular Section, is 
U.S. coordinator for an international study 
aimed at f inding out whether administering 
ketanserin, a serotonin antagonist, helps to 
extend the lives of patients suffering f r o m 
atherosclerosis and its complications. 
"As far as I know, this is the first t ime 
that a serotonin blocker has been tested i n 
this way , " says Dr. Cohen. " I t should te l l us 
a lot about the c l in ica l significance of what 
we've been doing . " • 
Suggested further reading 
1. Cohen, R.A. : Platelet-induced neurogenic coro-
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Canine artery mounted on 
wire stirrups for physiolog-
ical recording. 
The finding that sero-
tonin had the most 
direct effects in caus-
ing vasospasm was 
surprising, hecause 
many helieved throm-
hoxane to he the key 
factor. 
Complement's crucial role 
in bringing on a common 
disease of the kidney 
As many as 30 to 40 percent of adults w i t h 
nephrotic syndrome have membranous ne-
phropathy, a condi t ion that is a common 
cause of kidney failure. 
I n membranous nephropathy, the glomeru-
lus, w h i c h is the kidney's filtering mecha-
nism, becomes damaged. The result is that 
the kidney loses some of its selective filter-
ing capability, a l lowing large-sized protein 
molecules, especially a lbumin, to be excreted 
rather than retained i n the blood. The reduc-
t i o n i n serum a lbumin , i n t u r n , leads to the 
format ion of edema and the nephrotic syn-
drome. 
David J. Salant, M . D . , a member of the 
Evans Renal Section, says that membranous 
nephropathy may be a complicat ion of can-
cer, hepatitis and lupus, and is a side effect 
of various medications, inc luding gold, peni-
c i l lamine and captopril . Usually, though, i t 's 
a pr imary condi t ion . 
"Membranous nephropathy is most preva-
lent among the middle-aged, w i t h about a 
three-to-two preponderance of men over 
w o m e n , " says Dr. Salant, w h o also is an as-
sociate professor of medicine at BUSM. 
There are pal l iat ive treatments for ne-
phrot ic syndrome, and occasionally i t goes 
in to remission. Generally, though, the syn-
drome w i l l either settle d o w n i n t o a chronic 
state or produce kidney failure. 
There's no doubt that the membranous ne-
phropathy f o r m of the syndrome, when i t 's a 
pr imary condi t ion, is immunologic i n origin, 
says Dr. Salant. Biopsies show large i m m u n o -
globul in buildups at the site of the glomeru-
lar damage. N o t so clear, however, are the 
specific immune-system events that trigger 
the condit ion. 
Doubts about tbe prevailing view 
U n t i l about a decade ago, the accepted the-
ory was that membranous nephropathy re-
sults w h e n i m m u n e complexes circulating i n 
the bloodstream become trapped i n the k i d -
ney. But that theory didn ' t square w i t h find-
ings i n experiments w i t h rats. 
"One couldn' t reproduce membranous ne-
phropathy by introducing i m m u n e com-
plexes i n t o rats," explains Dr. Salant, "so 
certain people began to wonder whether the 
entrapment theory was correct." 
A m o n g the skeptics was W i l l i a m Couser, 
M . D . , an Evans investigator whose lab Dr. 
Salant joined i n 1977. [Dr. Couser left i n 
1982 to become chief of nephrology at the 
Univers i ty of Washington School of M e d i -
cine i n Seattle.) 
The Evans group determined that i m m u n e 
complexes i n the rat model i n fact f o r m in 
situ, w i t h the triggering mechanism being 
the binding of an antibody to a glomerular 
antigen. These findings matched those of 
D u t c h investigators w h o were exploring the 
origins of membranous nephropathy at about 
the same t i m e . (Subsequent studies by other 
groups have shown that the antigen involved 
is a component of glomerular epithelial 
cells.) 
Early studies of complement 
Dr. Salant and his colleagues also were i n -
terested i n the role of complement, the nine-
member f a m i l y of immune-system proteins 
best k n o w n for helping to combat such or-
ganisms as pneumococcus and gonococcus. 
" I t has been recognized for several 
years that y o u find complement components 
i n the diseased tissue f r o m patients w i t h 
membranous nephropathy," says Dr. Salant. 
A t the t i m e the group was beginning i ts 
studies, complement's only k n o w n role was 
to draw cells l i k e neutrophils to a target, and 
permit t h e m to carry out their destructive 
mission once on the scene. Other findings, 
however, suggested that complement was al-
most certainly not playing such a role i n 
membranous nephropathy. 
" I f y o u look under l ight microscopy at tis-
sue affected by membranous nephropathy, 
you w o n ' t see neutrophils or any other i n -
f lammatory cells," notes the investigator. 
"Since i t was thought that the only role of 
complement i n tissue in jury is through its 
influence on in f lammatory cells, the absence 
of such cells implies that complement is not 
i n v o l v e d . " 
But he and Dr. Couser, says Dr. Salant, 
suspected that complement m i g h t somehow 
be direct ly in jur ing the glomerulus, w i t h o u t 
having to call on neutrophils . To test their 
theory, they devised experiments i n v o l v i n g 
the rat model of membranous nephropathy. 
Initial tests of a theory 
The condi t ion is generated by injecting an-
tibodies that have an af f in i ty for an antigen 
located on the walls of glomerular capillar-
ies. " W h a t we d id first was to deplete some 
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'If you look under 
light microscopy at 
tissues affected hy 
memhranous nephro-
pathy, you won't see 
neutrophils or any 
other inflammatory 
cells.' 
Dr. Salant discusses effort to isolate antigen related to membranous nephropathy 
with technician Maryann Shea. Binding of antibody to antigen, which is located in 
wall of glomerular capillaries, triggers succession of events leading to creation of 
membrane attack complex. 
Photomicrograph shows glomerular capillary from rat kidney affected by early membranous nephropathy. 
Lower area (CL) is capillary lumen, area above (US) is urinary space. Dark spots denoted by arrows along 
eipthelial cell (Ep) borders are immune complexes. 
animals of complement , " says Dr. Salant. 
" T h e n we injected the antibody i n t o those 
animals and a group of controls. The group 
w i t h depleted complement did not develop 
a l b u m i n i n their ur ine , but the controls d i d . " 
Though the first sign that complement 
m i g h t indeed be direct ly involved i n damag-
ing the glomerulus, the experiments did not 
prove complement was playing such a role. 
"The idea was that perhaps inf lammatory 
cells were involved, and we s imply missed 
seeing t h e m , " says the investigator. "Maybe 
they just came through, did their 'd i r ty 
w o r k , ' and passed o n . " 
To check that possibility, the group per-
formed new experiments. They first reduced 
the levels of neutrophils and macrophages i n 
rats, and then induced membranous nephro-
pathy. This t ime , both sets of animals devel-
oped proteinuria. 
A l t h o u g h this was convincing evidence 
that complement does i ts damage directly, i t 
did not explain h o w that comes about. The 
investigators suspected that a compound 
made up of five of the complement proteins 
m i g h t be to blame. This compound, now 
called the membrane attack complex (MAC), 
had been found by other groups i n the m i d -
'70s. A l t h o u g h subsequently revealed to be 
responsible for the lysis of red blood cells 
and the destruction of bacteria, the com-
plex's potent ial for damaging kidneys had 
not been recognized by the t i m e the Evans 
investigators began their studies of i t . 
Probing how the damage is done 
To explore whether the complex was i n 
fact in jur ing glomerular membranes, there-
fore, the investigators performed a series of 
experiments, at the start using rabbits that 
were deficient i n one of the M A C proteins. 
Those experiments, and a subsequent se-
ries i n w h i c h plasma f r o m a patient deficient 
i n one of the M A C proteins was circulated 
through an in vitro rat kidney, helped p i n -
point the role of the membrane attack com-
plex. "We proved conclusively that the f u l l 
M A C is needed to produce a l b u m i n leakage 
i n experimental membranous nephropathy," 
says Dr. Salant. 
From microscopic studies of affected k i d -
neys, the group also was able to establish 
that glomerular epithel ial cells are the m a i n 
targets of the attack complex. So now they 
k n e w not only that complement was in jur ing 
the glomerular capillaries, but also how i t 
does so: The bui ldup of complement, t r ig-
gered by antigen-antibody linkages on the 
capillary walls , leads to format ion of the at-
tack complex. The complex, i n t u r n , attaches 
to the walls , creates holes i n them, and by a 
process s t i l l not f u l l y understood, alters their 
ab i l i ty to carry out normal filtering func-
tions. 
Ident i fy ing the attack complex as the chief 
culpr i t i n membranous nephropathy has 
raised the question of whether i t may be i n -
volved i n causing other conditions as w e l l . 
Other roles for the complex? 
"The complex has been found i n the sk in 
of patients w i t h lupus and bullous pemphi-
goid, and i n inf lamed muscle tissue f r o m pa-
tients w i t h dermatomyosit is , " notes Dr. Sal-
ant. " I t also has been identi f ied i n nerve 
tissue f r o m myasthenia gravis patients. I n 
addit ion, there's a study i n w h i c h M A C is re-
ported i n kidney samples f r o m patients w i t h 
a variety of different conditions, inc luding 
hypertension and diabetes." 
The simple fact that the complex is pres-
ent, he adds, doesn't i m p l y that i t 's playing a 
pathological role. Moreover, finding M A C 
does not rule out the possibi l i ty that comple-
ment is exerting its effects through its tradi-
t ional , indirect mode of action. 
" I n point of fact ," says Dr. Salant, "there's 
a k idney condi t ion that is caused by in f lam-
matory cells, and we've found that we can 
dist inguish i t f r o m membranous nephropathy 
s imply by determining the specific site 
w i t h i n the capillary w a l l at w h i c h the i m -
mune deposits f o r m . " 
Thinking about potential applications 
A t this point . Dr . Salant is t r y i n g to p i n 
down the specifics of the attack complex's 
effects on the kidney. Using glomerular epi-
thel ia l cell cultures, he hopes to pinpoint 
where and how i t does its damage. He also 
hopes to explore whether the complex oper-
ates the same way i n h u m a n kidneys as i n 
animal kidneys. 
Though the research has not yet reached 
the point of c l inical usefulness, the investi-
gator says he has given some thought to po-
tential applications. 
From a therapeutic standpoint, says Dr. 
Salant, one significant recent finding is that 
Continued on page 6 
E V A N S 
M E D I C I N E 
There's a study in 
which MAC is re-
ported in kidney sam-
ples from patients 
with a variety of dif-
ferent conditions, in-
cluding hypertension 
and diahetes.' 
Evans/Transition 
Richard Eglow, M . D . , has been named chief 
resident of the Evans for the 1986-1987 aca-
demic year. A native of Syosset, N.Y. , he re-
ceived his medical degree f r o m the Chicago 
Medical School. 
Dr. Eglow's m a i n research interest is the 
chemical makeup of the Clostridium difficile 
t o x i n B. He's current ly w o r k i n g w i t h investi-
gators f r o m the Section of Castroenterology 
i n an effort to sequence the tox in , w h i c h 
causes a v i ru lent f o r m of diarrhea i n some 
patients on ant ibiot ic regimens. 
" W h e n patients are put on antibiotics, and 
the drugs k i l l the other bacteria, i t permits 
C. difficile to secrete its toxins w i t h i n the 
l u m e n of the co lon , " explains Dr. Eglow. 
The tox in , one of t w o produced by C. diffi-
cile, is d i f f i c u l t to isolate because i t is very 
unstable, he adds. If i t can be sequenced, 
however, the investigators w i l l then be able 
to compare i t w i t h other toxins, such as the 
cholera t o x i n , i n an effort to better under-
stand its mode of action i n the colon. 
D r Eglow, w h o came to the Evans after 
graduating f r o m medical school, says he ex-
pects to become a fe l low i n the Section of 
Gastroenterology f o l l o w i n g complet ion of his 
service as chief resident. 
The chief resident also is an ardent Yan-
kees fan—a passion that stems i n part, he 
says, f r o m the fact that Joe Dimaggio is a 
close f a m i l y fr iend. 
Yet despite the fact that he has a large 
Yankee poster and t w o pictures of Dimaggio 
i n his office. Dr. Eglow doesn't begrudge Red 
Sox fans their team's success this past sea-
son. "They waited a long t i m e for i t , " he 
says graciously. 
A tota l of 17 interns have joined the Evans 
this year. They are: 
Lee Albert, M.D. , Johns Hopkins School of 
Medicine 
Jeffrey Altholz, M.D. , Einstein College of 
Medicine 
David Cohen, M.D. , Jefferson Univers i ty 
Medical College 
Susan DeCoste, M.D. , Univers i ty of Con-
nect icut School of Medic ine 
Mary Delaney, M.D. , Boston Univers i ty 
School of Medicine 
Katherine Duffy, M.D. , Univers i ty of Mary-
land School of Medicine 
Richard Fogel, M.D. , Brown Univers i ty 
School of Medicine 
Michael Goldaber, M.D. , Albany Medical 
College 
Dale Janik, M.D. , Univers i ty of Pennsylvania 
School of Medicine 
Michael Kraut, M.D. , Einstein College of 
Medicine 
Michael Lev, M.D. , Brown Univers i ty School 
of Medicine 
Scott Mackler, M.D. , Univers i ty of Pennsyl-
vania School of Medic ine 
Max Rosen, M.D. , Tufts Univers i ty School of 
Medicine 
Harry Shapiro, M.D. , Boston Univers i ty 
School of Medicine 
Dr. Eglow (foreground) checking patient's chart in U H ' s Medical Intensive Care 
Unit with resident Robert M . Weiss, M . D . , and Nadine Barry, R .N. , staff nurse. 
M I C U is located on seventh floor of Evans Building. 
Alice Sheridan, M.D. , N e w York Medical 
College 
DuWayne Willett, M.D. , Univers i ty of Wis-
consin School of Medicine 
John Wilson, M.D. , Pennsylvania State U n i -
versity School of Medicine. 
This past year's Evans graduates, and their 
current pursuits, are: 
Lynne Brodsky, M.D. , Boston Univers i ty 
Medical Center (geriatrics) 
Richard Eglow, M.D. , The Univers i ty Hospi-
tal (chief resident) 
Steven Feske, M.D. , primary-care practice, 
Boston area 
Howard Fogel, M.D. , Massachusetts General 
Hospital (endocrinology) 
Stephan Gaehde, M.D. , Boston Veterans A d -
m i n i s t r a t i o n Medical Center 
Kamran Ghalili , M.D. , The Univers i ty Hos-
p i ta l (cardiology) 
Bruce Kriegel, M.D. , primary-care practice, 
Boston area 
Vanessa Lucarella, M.D. , Univers i ty of Penn-
sylvania (cardiology) 
Judith Melin, M.D. , Eahey Cl in ic (general i n -
ternal medicine) 
Chester Mohr, M.D. , N e w England Medical 
Center (pulmonary medicine) 
Debra Nichols, M.D. , Carney Hospital , Bos-
ton (chief resident) 
Daniel O'Dea, M.D. , Valhalla Westchester 
County Medical Center (cardiology) 
Jerome Siegel, M.D. , Bedford (Mass.) Veter-
ans A d m i n i s t r a t i o n Medical Center (geria-
trics) 
Zachary Spigelman, M.D. , The Univers i ty 
Hospital (oncology) 
David Strumpf, M.D. , Rhode Island Hospital , 
Providence (pulmonary medicine). • 
Evans Memorial Department N o n p r o f i t Org. 
of Clinical Research U.S. Postage 
The Univers i ty Hospita l PA ID 
75 East N e w t o n Street Boston, M A 
Boston, M A 02118 Permit N o . 3469 
Noteworthy 
Linda Lesky, M.D. , has been named a mem-
ber of the Evans Section of General Medi -
cine. A graduate of the Univers i ty of Chicago 
School of Medicine, Dr. Lesky did her resi-
dency at Michael Reese Hospital i n Chicago. 
She also served as medical director of that 
hospital's internal medicine c l inic and as d i -
rector of a preventive medicine fac i l i ty i n 
Chicago. I n addit ion to her Evans appoint-
ment . Dr . Lesky has been named to the gen-
eral medicine staff of The Univers i ty Hospi-
ta l and w i l l head the new Women's Heal th 
Group of U H ' s Evans Medical Group. She 
has also been appointed an assistant profes-
sor of medicine at Boston Univers i ty School 
of Medicine. 
David M . Center, M.D. , has been appointed 
chief of the Evans Pulmonary Section. Dr. 
Center succeeds Jerome S. Brody, M.D. , w h o 
w i l l continue to be active i n the Section. Dr. 
Brody heads Boston Univers i ty School of 
Medicine 's Pulmonary Center. 
Complement. 
Continued from page 4 
thromboxane and other arachidonic-acid 
products play a supporting role to comple-
ment i n damaging the kidney. Complement, 
he notes, triggers the output of these prod-
ucts, and they i n t u r n appear to aggravate the 
damage. 
"By the t i m e we see membranous nephro-
pathy, the disease usually is established," he 
notes. "But we have effective blockers for 
these arachidonic-acid products, so we can 
t h i n k about i n h i b i t i n g some of their effects, 
and perhaps reducing the amount of damage 
sustained by the k idney . " • 
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Gordon L . Snider, M.D. , is serving as presi-
dent of the Amer ican Thoracic Society, the 
medical arm of the American Lung Associa-
t i o n . Dr. Snider, a member of the Evans Pul-
monary Section, was recently named chief of 
medicine at the Boston Veterans Adminis t ra -
t i o n Medical Center. 
Joseph Stokes I I I , M.D. , a member of the 
Section of Preventive Medicine and Epide-
miology, has been named editor of the Amer-
ican Journal of Preventive Medicine. The ap-
pointment took effect July I , and the first 
issue prepared under Dr. Stokes' direct ion 
w i l l appear i n January 1987. Dr. Stokes is a 
principal investigator for the Boston Univer-
sity-Framingham Heart Study. 
William E. Huckabee, M.D. 
1926-1986 
W i l l i a m E. Huckabee, M . D . , a member of the 
Evans f r o m 1950 to I 9 7 I , died i n July of this 
year. 
Dr. Huckabee, w h o headed the Evans Sec-
t i o n of Cardiac Metabol ism, carried out land-
mark investigations that brought h i m inter-
nat ional renown. His major research finding, 
published i n 1958, was that the rate of cellu-
lar respiration is reflected i n the ratio of lac-
tate to pyruvate i n the h u m a n body, w i t h a 
disproportionate increase i n lactate indicat-
ing cellular dysfunct ion. I n later papers, he 
described and defined the c l inical problem of 
lactate acidosis, an important concept that is 
s t i l l under investigation. 
Dr. Huckabee was a professor of medicine 
at Boston Univers i ty School of Medicine. He 
served as president of the American Federa-
t i o n of Cl in ica l Research f r o m 1965 to 1967. 
He was also associate editor of the Journal of 
Clinical Investigation. 
Born i n 1926 i n Brownwood, Texas, Dr. 
Huckabee received his undergraduate educa-
t i o n at Southern Methodist Univers i ty i n 
Dallas, and earned his medical degree at the 
Southwestern Medical College of the Univer-
sity of Texas, also i n Dallas. He intemed at 
Massachusetts M e m o r i a l Hospitals (now The 
Univers i ty Hospital) and was a cardiology 
fe l low under the late Robert W. W i l k i n s , 
M . D . , former director of the Evans. 
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